New drug option for early Alzheimer’s

UW Medicine administered its first dose of intravenous lecanemab to a patient.

Media Contact: Susan Gregg - 206-390-3226,

A drug shown to reduce cognitive decline in patients with early Alzheimer’s disease was administered Friday, Dec. 1, to patient Doug Davidson at UW Medicine’s Memory and Brain Wellness Center.  

Davidson's IV infusion of lecanemab marked the the first time Harborview Medical Center has provided the therapy to a qualifying patient. Harborview is one of the first West Coast hospitals to offer the drug, which was approved this year by the U.S. Food and Drug Administration. 

Details in our news release. Download broadcast-ready video of Davidson receiving the first lecanemab infusion at UW Medicine.

UW Medicine